Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include new phase 2 data on CT-388 for obesity, the US Food and Drug Administration (FDA) approval of a labeling supplement permitting repeat administration of travoprost intracameral implant (iDose TR) in open-angle glaucoma or ocular hypertension, new American Society of Hematology (ASH) guidelines on light chain (AL) amyloidosis, the FDA approval of carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (Yuvezzi) for presbyopia, and the US Centers for Medicare & Medicaid Services selection of 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first-ever Part B drugs.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of January 25, 2026—let’s jump in!

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

On January 27, 2026, Genentech, a member of the Roche Group, announced positive topline results from CT388-103, a phase 2 clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity.

Results showed once-weekly subcutaneous injections of CT-388 titrated up to 24 mg resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. A clear dose-response relationship on the weight loss was also observed.

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

On January 28, 2026, the FDA approved a labeling supplement permitting repeat administration of travoprost intracameral implant (iDose TR) for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The update modifies prior labeling that limited use to a single administration and is based on accumulated clinical safety data, including corneal endothelial outcomes, submitted by the manufacturer.

ASH Releases New Clinical Practice Guidelines for Diagnosing AL Amyloidosis

On January 28, 2026, ASH published new clinical practice guidelines aimed at improving the early, timely, and accurate diagnosis of AL amyloidosis. The document, published in 

, outlines best practices to support clinicians in recognizing and diagnosing AL amyloidosis, a disease frequently missed or diagnosed late due to its heterogeneous presentation.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

On January 28, 2026, the FDA approved Tenpoint Therapeutics’ carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (Yuvezzi) for the treatment of presbyopia in adults, representing the first regulatory authorization of a fixed-dose, dual-agent topical therapy for age-related near vision degradation.

CMS Selects 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program

On January 27, 2026, the US Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B for the third cycle of the Medicare Drug Price Negotiation Program. CMS additionally selected 1 previously negotiated drug, linagliptin (Tradjenta), for the program’s first renegotiations. Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028.

Articles

Genentech's phase 2 trial of CT-388 for obesity demonstrated significant weight loss without plateauing at 48 weeks. The FDA approved a labeling update for iDose TR, allowing repeat administration for open-angle glaucoma and ocular hypertension. ASH released new guidelines for diagnosing AL amyloidosis to improve early detection. The FDA approved Yuvezzi, the first dual-agent eye drop for presbyopia. CMS selected 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including Part B drugs, with negotiations set for 2026 and prices effective in 2028.

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hematology

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 01/25

Pre-Symptomatic Detection of Crohn’s Disease Through Flagellin Antibodies, With Sun-Ho Lee, MD, PhD

Crohn’s disease is typically diagnosed only after patients develop overt gastrointestinal symptoms, yet mounting evidence suggests that the pathogenic process begins years earlier.

During this silent, preclinical phase, immune dysregulation and host-microbe interactions may already be driving disease evolution. Understanding these earliest events has become a key priority in inflammatory bowel disease research, with the goal of identifying biomarkers that can predict risk, inform surveillance, and ultimately enable strategies to delay or prevent disease onset.

A new study from the Lunenfeld-Tanenbaum Research Institute and Mount Sinai Hospital’s Center for Inflammatory Bowel Disease has identified a blood test that can predict Crohn’s disease years before symptoms appear by measuring a person’s immune response to flagellin.

“Up until this study, it was unclear, especially in healthy first relatives, what type of flagellin antigens were the drivers or triggered the immune response, and if these antibody responses were associated with other biomarkers that are related to onset of Crohn's,” study investigator Sun Ho Lee, MD, PhD, a gastroenterologist at Sinai Health Zane Cohen Centre for Digestive Diseases, told 

Seeking to address that gap and build upon previous research regarding immune response against gut microbes prior to Crohn’s diagnosis, he and a team of investigators followed 381 first-degree relatives of Crohn’s patients as part of the Genetic, Environmental, and Microbial (GEM) Project, a global cohort of > 5000 healthy first-degree relatives of people with Crohn’s disease. Among the population in the present study, 77 went on to develop the disease.

Using 2 complementary assays, the researchers evaluated antibody responses to 49 recombinant flagellin antigens. Results showed 19 of 49 IgG antimicrobial antibody responses were significantly associated with the risk of Crohn’s. These antibodies were reactive to the Lachnospiraceae family, particularly Roseburia-derived flagellins.

Additionally, 5 antibodies positively correlated with fecal calprotectin, whereas 3 positively correlated with lactulose-to-mannitol ratio. Of note, these IgG-seroreactive flagellins shared significant amino acid sequence homology, characterized by a conserved "hinge peptide" within D0-D1 domains of the amino-terminus. The cytometric bead array confirmed that elevated IgG seroreactivity to the hinge peptide is associated with future risk of Crohn’s, independent of both lactulose-to-mannitol ratio and fecal calprotectin.

Taken together, Lee emphasized that these findings help refine the understanding of preclinical Crohn’s disease and narrow the focus to specific microbial antigens and epitopes. He suggested that such highly specific immune signatures could form the basis for future biomarkers aimed at identifying individuals at risk of Crohn’s before clinical symptoms emerge.

Editors’ Note: Lee reports no relevant disclosures.

Wu RY, Xue M, Zhao Q, et al. Serum IgG Response to a Conserved Domain of Commensal Flagellins Predicts Future Risk of Crohn's Disease in First-degree Relatives. 

Lunenfeld-Tanenbaum Research Institute. A simple blood test can predict Crohn’s disease years before symptoms appear. EurekAlert! 

https://www.eurekalert.org/news-releases/1111855

Videos

Lee explains what is known about the preclinical phase of Crohn’s disease before symptoms appear and describes his study on the role immune dysregulation plays.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Gianluca Florineth, MSc, from the Translational Research Center, University Hospital of Psychiatry and Psychotherapy at the University of Bern in Switzerland.

Preparation Improves Psychedelic Therapy for MDD, With Gianluca Florineth, MSc

Longer follow-up periods and therapy design choices may influence outcomes in psychedelic-assisted therapy (PAT) for 

, a recent meta-analysis found. The study highlights preparation therapy as a key factor in symptom reduction, while post-dosing integration sessions and total therapy duration showed no significant association with short-term outcomes.

spoke with investigator Gianluca Florineth, MSc, from the Translational Research Center at the University Hospital of Psychiatry and Psychotherapy, University of Bern, on this research. Despite many studies in the analysis having a high risk of bias due to ineffective blinding, Florineth has confidence in the strength of the association between preparation therapy and positive outcomes.

“It's a limitation that is very difficult to control in psychedelic research because the blinding is one of the most significant challenges that are faced in randomized trials using psychedelics, because the effects are so noticeable that participants can distinguish them if you assess it most of the time, over 95% probability,” Florineth said. “In my opinion, this doesn't really influence our findings that much because we look at this treatment as a combination of psychological and pharmacological therapy.”

He believes that the therapeutic processes occurring during preparations are not affected by this risk of bias. While these biases may influence the overall treatment effect, the relationship between therapeutic factors and symptom reduction is likely less affected.

Florineth’s team pooled data from 12 controlled trials, including 733 adults (49.8% female; mean age 42.1) receiving psilocybin- or LSD-assisted therapy. They examined associations between depressive symptom change and therapy-related variables, including preparation hours, integration hours, total therapy exposure, and overall treatment duration.

Each additional hour of preparation therapy correlated with greater depressive symptom reduction (

 =.04), whereas integration therapy hours (

=.86) were not significantly associated with short-term outcomes. Longer follow-up periods were linked to smaller effect sizes (

 =.003), consistent with the natural attenuation of therapeutic benefits over time. Most studies (75%) carried a high risk of bias, primarily due to ineffective blinding.

The findings suggest that preparation therapy may directly influence symptom reduction, while integration sessions and total therapy time likely serve other roles, such as consolidating therapeutic insights and maintaining gains, which are not captured by short-term depression measures. Factors such as therapeutic alliance, therapist experience, and patient readiness may critically shape outcomes, potentially outweighing the quantity of sessions.

From a trial design perspective, the study highlights the importance of reporting and evaluating psychological therapy components, including comparisons of high- versus low-support conditions and therapy intensity. For clinical implementation, the results underscore the need to consider psychedelics within a framework that integrates psychotherapy, regulatory guidance, therapist training, and minimum support standards to achieve and sustain clinical benefit.

“We hope that the role of psychological therapy will not just be dismissed,” Florineth said. “We see somewhat of a trend currently because of the FDA rejection of MDMA-assisted therapy, which was in some parts due to this unclear role of psychological therapy or this combination approach. Now, as a solution, some have started to prohibit the use of psychotherapy in their trial designs so that they can say it's a purely pharmacological intervention, but we think that this is a bit dangerous if you haven't really assessed the psychological therapy itself or its potential role or benefits. We hope that this gives at least some ideas that the role of psychological therapy should be explored further before we draw preliminary conclusions without really assessing it.”

Florineth GA, Klima I, Boeker AL, et al. Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2026;9(1):e2554843. Published 2026 Jan 2. 

Derman C. Preparation Before Psychedelics Tied to Better MDD, With Gianluca Florineth, MSc. HCPLive. Published on January 26, 2026. Accessed on January 30, 2026. 

https://www.hcplive.com/view/preparation-before-psychedelics-tied-better-mdd-gianluca-florineth-msc

Meta-analysis links longer preparation therapy and follow-up duration to depressive symptom change in psilocybin- and LSD-assisted treatment. 

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

New phase 3 data on risankizumab suggest the treatment is both effective and safe over 52 weeks among pediatric patients with moderate-to-severe psoriasis.

 in a poster titled, ‘Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis in the OptIMMize-1 Phase 3 Study: Results Through 52 Weeks.’ These data were authored by such investigators as Nina Magnolo, MD, from the University Hospital of Münster’s Department of Dermatology.

Magnolo et al’s analysis was aimed at evaluating long-term outcomes with risankizumab therapy in children and adolescents aged 6 years and older who lived with moderate-to-severe plaque psoriasis. These patients were also eligible for systemic drugs. In their background section, the investigators highlighted the chronic nature of psoriasis and its characteristic symptoms, including dryness, pruritus (itch), irritation, and pain, all of which can significantly disrupt daily functioning.

Despite the existence of advanced systemic treatments for adults with psoriasis, therapeutic options combining robust efficacy with long-term safety data remain more limited in younger populations, underscoring the need for additional pediatric-focused research on risankizumab. The drug itself is a humanized IgG1 monoclonal antibody designed to selectively target interleukin (IL)-23 by binding to its p19 subunit.

Prior results from the pediatric OptIMMize-1 study showed, following 16 weeks of risankizumab treatment, children and adolescents experienced improvements in their levels of pruritus, skin clearance, and quality of life, with tolerability shown to be comparable to adults.

 In this report, Magnolo and coauthors extend these findings by assessing efficacy and safety outcomes through 52 weeks of treatment.

In the phase 3 OptIMMize-1 study, investigators used a multicenter, four-part clinical trial design (NCT04435600), with Parts 1 and 3 evaluating the pharmacokinetics of risankizumab to help determine appropriate dosing. These portions are not included in this analysis. In Part 2, the investigative team enrolled adolescents in a randomized, efficacy assessor–blinded design.

The study’s initial 16-week active-controlled period involved randomization of the participants in a 2:1 ratio to be treated with risankizumab or ustekinumab. During the subsequent period included, subjects would either continue their treatment for up to 36 weeks or withdraw. At the 16-week mark, those originally treated with ustekinumab, as well as risankizumab nonresponders (defined by a static Physician’s Global Assessment score of 2 or higher), transitioned to risankizumab administered every 12 weeks through the 40-week mark.

Adolescents shown to respond to risankizumab at the 16-week mark, defined as those with an sPGA score of 0 or 1, were rerandomized to either continue risankizumab dosing every 12 weeks or discontinue the drug until disease flare, defined as an sPGA score of 3 or higher on or after Week 28. Those with flares after withdrawal entered a 16-week retreatment phase.

In Part 4, investigators used an open-label component including children between 6 - 12 years, all of whom received risankizumab for a total of 52 weeks. Across pediatric participants with moderate-to-severe psoriasis, Magnolo and colleagues identified a general continuation of clinical benefits at Week 16, or further improvements, through Week 52 with ongoing risankizumab use.

Such improvements included measures of skin clearance, reduction in pruritus, and quality of life shifts.

 Most adolescents who reported disease worsening following treatment withdrawal were able to recapture clinical responses following the 16-week retreatment period. Throughout the 52-week study’s duration, the medication was well-tolerated in both children and adolescents. Additionally, Magnolo et al pointed to its safety profile being consistent with findings previously reported in adult psoriasis populations.

“Together, these findings support the use of risankizumab to treat pediatric patients with moderate-to-severe psoriasis,” Magnolo and colleagues wrote.

Magnolo N, Lee L, Paller A, et al. Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis in the OptIMMize-1 Phase 3 Study: Results Through 52 Weeks. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Pang Y, D'Cunha R, Winzenborg I, Veldman G, Pivorunas V, Wallace K. Risankizumab: Mechanism of action, clinical and translational science. Clin Transl Sci. 2024 Jan;17(1):e13706. doi: 10.1111/cts.13706. PMID: 38266061; PMCID: PMC10777435.

Phase 3 data indicate that risankizumab is effective and safe for pediatric patients with moderate-to-severe psoriasis over 52 weeks. The study involved children and adolescents aged 6 and older, highlighting the chronic nature of psoriasis and the need for pediatric-focused treatments. The OptIMMize-1 study showed improvements in pruritus, skin clearance, and quality of life, with a safety profile consistent with adult data. The study's design included a randomized, efficacy assessor–blinded approach, and the drug was well-tolerated, supporting its use in pediatric psoriasis treatment.

The Maui Derm Hawaii 2026 conference featured a poster presentation highlighting recent phase 3 findings on risankizumab in pediatric patients.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

OptIMMize-1: New Efficacy and Safety Data on Risankizumab in Pediatric Psoriasis

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Identifying the Missing Link in Viral Hepatitis Elimination Efforts

In this segment of Liver Lineup, Nancy Reau, MD, and Kimberly Brown, MD, revisit the ongoing challenge of meeting 

 elimination targets, despite the availability of curative and highly effective therapies. Referencing recent observatory data compiled through collaborations between the World Health Organization and the US Centers for Disease Control and Prevention (CDC), the discussion underscores a persistent disconnect between what is possible scientifically and what is happening in real-world clinical practice.

Reau frames the issue bluntly, asserting that viral hepatitis remains a set of diseases that can be cured or well controlled, yet health systems are still falling short of elimination goals. While Brown acknowledges that her institution still lags behind in certain aspects, she highlights a notable success with eliminating viral hepatitis within a closed dialysis population by implementing a strategy built on universal testing.

Of note, instead of relying on referrals or action from outside clinicians, patients were screened systematically, and those who tested positive were proactively contacted and treated. According to Brown, this model demonstrated that elimination is achievable when identification and treatment are tightly integrated, but it also revealed that relying on individual providers to initiate screening can be a major barrier.

Both experts agree that patient identification remains the central obstacle. Screening for hepatitis B and C often falls to primary care, while hepatologists are left to manage treatment once patients are referred. Reau notes that even in systems with robust screening programs in high-risk settings, such as emergency departments and urgent care centers, linkage to care can be difficult, particularly for patients who are not already established within the health system.

Reau also expresses frustration with referrals for abnormal liver enzymes that lack basic hepatitis B and C testing. While acknowledging that viral hepatitis is not the most common cause of abnormal liver chemistries, she emphasizes that standard screening remains widely recommended and should not be overlooked. The absence of this testing, she argues, reflects missed opportunities for diagnosis rather than thoughtful exclusion.

Brown echoes that screening has improved at her institution, noting that patients she sees with elevated liver enzymes are now routinely tested for hepatitis B and C, even when the ultimate diagnosis is MASLD. Together, the discussion highlights that meaningful progress toward hepatitis elimination will depend less on new therapies and more on systematic screening, proactive outreach, and closing persistent gaps in care delivery.

Editors’ note: Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Manning J, Ward J, Hiebert-Suwondo L. Global Progress toward the Elimination of Hepatitis B: Country-Level Provisional Achievements of WHO Targets for Prevention, Care, and Reductions in Mortality. Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

Ching Z, Hiebert-Suwondo L, Ward J. Global Progress Toward Hepatitis C Elimination: Monitoring Achievements of WHO Goals and Targets for Hepatitis C Prevention and Care. Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

In this segment, Nancy Reau, MD, and Kimberly Brown, MD, discuss ongoing challenges with viral hepatitis elimination efforts and clinical shortcomings in screening.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Video Series

Hope on the Horizon: The Future of GCA Treatment

Reflecting on Trial Limitations in GCA: Painting a Future for IL-17A Targeting Therapies 

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

With the acceptance, the FDA has assigned the oral phosphate binder a Prescription Drug User Fee Act target action date of June 29, 2026.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

FDA News

FDA Accepts Oxylanthanum Carbonate NDA Resubmission for Hyperphosphatemia in CKD, Dialysis

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

The FDA approval is based on a pair of phase 3 trials, including the larfest and longest safety study of presbyopia eye drops. 

Dawn Eichenfield, MD, PhD, is a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at UC San Diego School of Medicine.

This Q&A interview with Dawn Eichenfield, MD, PhD, highlights notable takeaways from her session at Maui Derm Hawaii titled ‘Pediatric Dermatology 2026.’

Spotlighting Pediatric Dermatology Updates for 2026, With Dawn Eichenfield, MD, PhD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

Emerging Psoriasis, PsA Drugs and Future Developments in Dermatology, With Linda Stein Gold, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

ASH’s multidisciplinary panel provides a standardized diagnostic pathway emphasizing early laboratory testing and surrogate biopsies.

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

Noureddin recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

This interview at the 2026 Maui Derm Hawaii meeting features a discussion of new and emerging therapies in psoriasis, including icotrokinra.

Discussing Icotrokinra for Adolescents, Other Emerging Psoriasis Drugs, With Linda Stein Gold, MD

Podcasts

Reau and Brown discuss new data on MASH/MASLD, including awareness, referral patterns, discussions around alcohol, and emerging pharmacotherapies.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 01/25

Pre-Symptomatic Detection of Crohn’s Disease Through Flagellin Antibodies, With Sun-Ho Lee, MD, PhD

Preparation Improves Psychedelic Therapy for MDD, With Gianluca Florineth, MSc

OptIMMize-1: New Efficacy and Safety Data on Risankizumab in Pediatric Psoriasis

Identifying the Missing Link in Viral Hepatitis Elimination Efforts